MedTrace Logo

Ceftriaxone in the Management of Bipolar Depression

NCT00566111 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-03-31

Study results available
· View outcomes & findings →

Summary

We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.

Conditions

Interventions

DRUG

ceftriaxone

2g per day which will be administered IV via midline, 7 days a week for 4 weeks.

DRUG

Saline solution

Saline solution will be administered IV via midline, 7 days a week for 4 weeks.

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Zubin Bhagwagar, MD PhD · Yale University

  • Gerard Sanacora, MD PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00566111 on ClinicalTrials.gov